Welcome to our dedicated page for Eyenovia SEC filings (Ticker: EYEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eyenovia, Inc. (EYEN) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as it transitions to operating under the name Hyperion DeFi, Inc. These filings include Current Reports on Form 8-K that describe material events such as the corporate name change from Eyenovia, Inc. to Hyperion DeFi, Inc., the anticipated Nasdaq ticker change from EYEN to HYPD, and the launch of a new cryptocurrency treasury strategy focused on the HYPE token native to the Hyperliquid blockchain.
In its 8-K filings, the company supplements its business description and risk factors to explain its dual focus on digital ophthalmic technology and building a long-term strategic treasury of HYPE. Investors can review details of the private placement used to fund HYPE acquisitions, the structure of preferred stock and warrants issued in that transaction, and amendments to loan agreements that adjust maturity dates, interest rates and related warrant grants. These documents also outline the company’s plan to implement a HYPE staking program and operate a co-branded validator on Hyperliquid.
Filings further describe the Optejet User Filled Device (UFD), including its intended use with various topical ophthalmic liquids and its role in the company’s ophthalmic business. Risk factor disclosures address potential volatility in the price of HYPE, regulatory and market risks associated with digital assets, and other considerations that may affect the company’s financial condition and share price.
On Stock Titan, users can access these SEC filings as they are made available through EDGAR, along with AI-powered summaries that highlight key points from 8-Ks and other reports. This helps readers quickly understand how corporate actions, financing arrangements, digital asset strategies and device development updates are reflected in Eyenovia’s official regulatory record under the EYEN symbol and its subsequent Hyperion DeFi, Inc. identity.
Eyenovia announced a significant strategic shift through a $50 million private placement and entry into cryptocurrency markets. The company sold 5,128,205 shares of Series A Non-Voting Preferred Stock and warrants to institutional investors, with each preferred share convertible into three common shares.
Key developments include:
- Appointment of Hyunsu Jung (age 29) as Chief Investment Officer and Director, with a $250,000 salary and equity incentives
- Plans to build reserves of HYPE tokens and implement a staking program while continuing development of Gen-2 Optejet Device
- Board restructuring with resignations of Sean Ianchulev, Charles Mather IV, and Ram Palanki
- Amendment to loan agreement with Avenue Capital, extending maturity to 2028 and reducing interest from 12% to 8%
The private placement includes warrants exercisable at $3.25 per share after six months, with Chardan Capital Markets acting as placement agent. The company's pro forma shares outstanding would increase to 54,027,429 upon full conversion of preferred shares and warrant exercise.
Avenue Capital Management II has filed a Schedule 13D/A (Amendment No. 3) regarding their holdings in Eyenovia, reporting significant ownership changes through multiple investment vehicles. The filing reveals:
Key Investment Vehicles & Holdings:
- Avenue Venture Opportunities Fund L.P. owns 174,175 shares (4.0%)
- Avenue Venture Opportunities Fund II L.P. holds 261,263 shares (5.99%)
- Avenue Capital Management II L.P. controls 435,438 shares (9.99%)
The funds collectively hold warrants to purchase an additional 250,000 shares at $4.00 per share, though these are subject to a 9.99% beneficial ownership blocker. Total shares outstanding as of June 5, 2025: 4,358,755. Avenue Capital Management II L.P. serves as the manager with sole voting and dispositive power over all securities held by the funds.